Molecularly targeted therapies for colorectal cancer: Strategies for implementing translational research in clinical trials.

摘要: Few breakthroughs in preclinical research have translated into meaningful benefits, either clinical terms or quality of life, for patients with advanced colorectal cancer, despite important discoveries regarding aberrant biological pathways associated disease development and progression. The many reasons the slow progress are diverse, ranging from failure to codevelop biomarkers targeted therapies, regulatory burdens imposed on academic investigators, collect serial tumor biopsies during trials. This review discusses promising translational that could help reduce disparity between discovery patient benefit, advocate concentration efforts resources most therapeutic targets such as EGFR, VEGF Fcγ receptor.